Table 3.
ICS doses by formulation and age
| Drug | Daily dose ug (age ≤ 5 years) | Daily dose ug (age 6–11 year) | Daily dose ug (age ≥ 12 years) | ||||
|---|---|---|---|---|---|---|---|
| Lowa | Low | Medium | High | Low | Medium | High | |
| Betamethasone Dipropionate (CFC) | - | 100–200 | >200–400 | >400 | 200–500 | >500–1000 | >1000 |
| Betamethasone Dipropionate (HFA) | 100 | 50–100 | >100–200 | >200 | 100–200 | >200–400 | >400 |
| Budesonide (pMDI + spacer) | 200 | - | - | - | - | - | - |
| Budesonide (DPI) | - | 100–200 | >200–400 | >400 | 200–400 | >400–800 | >800 |
| Ciclesonide | 160 | 80 | >80–160 | >160 | 80–160 | >160–320 | >320 |
| Fluticasone propionate (DPI) | - | 100–200 | >200–400 | >400 | 100–250 | >250–500 | >500 |
| Fluticasone propionate (HFA) | 100 | 100–200 | >200–500 | >500 | 100–250 | >250–500 | >500 |
| Mometasone furoate | Not studied below 4 years | 110 | 220–<440 | ≥440 | 110–220 | >220–440 | >400 |
| Triamcinolone acetonide | Not studied | 400–800 | >800–1200 | >1200 | 400–1000 | >1000–2000 | >2000 |
HFA hydrofluoroalkane propellant
aA low daily dose is defined as the dose that has not been associated with clinical adverse effects in trials that included measures of safety
Modified from GINA 2015 [3]